Navigation Links
U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November

CAMBRIDGE, Mass., June 7, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it will present Congressman Michael Capuano (D-MA) with its first ever "Lou Gehrig Award" during its annual A White Coat Affair gala event this November 3rd.  The award recognizes the Congressman for his tireless efforts in Congress to advocate for additional funding for research leading to an effective treatment for ALS.


"As a person battling ALS today, I wish to thank Congressman Capuano for his stand against this disease.  The attention and funding that he has helped to bring to this killer has brought new researchers, new ideas and frankly renewed hope that people like me will one day truly have the chance to fight this disease back," said Augie Nieto, chairman of the Board of ALS TDI.

The award will be presented during the Institute's annual gala event, A White Coat Affair, to be held at the Hotel Marlowe in Cambridge, Mass.  The Congressman will be recognized during a special ceremony being organized by ALS TDI.  Additional information is available online at or by calling 617-441-7205.  The Lou Gehrig name is used with the permission of the Rip Van Winkle Foundation.  

"Time and time again Congressman Capuano has shown that he understands the hardship faced by those living with Lou Gehrig's disease today.  Congressman Capuano's support of ALS TDI's unique approach has inspired others in Congress to join together in a focused effort to fund this groundbreaking and crucial research.  This is a cause that he has championed and we are honored to recognize him for his leadership and persistence on behalf of patients today," said Steve Perrin, Ph.D., CEO and CSO of ALS TDI.

About ALS Therapy Development Institute

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Founded by the family of an ALS patient in 1999 as the world's first "nonprofit biotech", ALS TDI is now internationally recognized as a leading medical research institution.  Its unique industrial-scale platform actively develops and tests dozens of potential therapeutics each year.  The Cambridge, Massachusetts, based research Institute collaborates worldwide with academia and industry to bridge the translational research gap which exists among many orphan diseases, such as ALS.  For more information about the Institute's current research pipeline and to take a virtual lab tour, please visit us online at

Media Contact: Robert A. Goldstein, ALS TDI, 617-441-7295,

SOURCE ALS Therapy Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinsons Cure
2. Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
3. Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team
4. NxStage® Names Michael Miller, Jr. President, International
5. Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
6. Michael Douglas, Honored Film Star and Throat Cancer Survivor, Encourages Public to Attend Free Local Screenings During Oral, Head & Neck Cancer Awareness Week
7. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
8. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
9. Hill-Rom Elects Michael Macek as Treasurer
10. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
11. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
Post Your Comments:
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women on ... organizations in the country. They have overseen financial turnarounds, shown commitment to their ... healthcare industry as a whole through their advocacy and professional efforts. , Becker's ...
Breaking Medicine News(10 mins):